
ALK+ Blog/News
- ALK Experts
- ALK International
- ALK Positive News
- Clinical Trials
- Government
- Living with ALK+
- Nutrition
- Patient & Care Partner Stories
- Powered By Patients
- Recipes
- Research
-

Butternut Squash Hummus Recipe by Fellow ALKie, Juli Posner
Juli Posner is a personal chef on Long Island, New York, diagnosed with ALK-Positive lung cancer in January of 2020. Formerly the Producer of a PBS network cooking show, she now concentrates on her personal clients’ individual culinary needs and is always looking to make eating healthy and exciting without sacrificing flavor. A born “LIVE…
-

ALK Clinical Trials September 2024: Should Brain Metastases be Treated with Radiation at Diagnosis in ALK+ Lung Cancer? Research About a Crucial Question
For those facing the challenging diagnosis of ALK-positive lung cancer, brain metastases often pose a serious concern. Research reveals that up to 40% of these patients have brain metastases right from the start. This sets the stage for a critical question in treatment planning: Is it better to tackle these brain metastases with spot radiation,…
-

Healthy Eggplant Stacks A recipe by chef and fellow ALKie, Juli Posner
If you think you don’t like eggplant this will change your mind. This recipe has all the feels. Warm, cheesy, melty, straight from the oven. I make it with any ground meat I have on hand. What’s also nice is that it’s baked and not fried. So you can have that second helping. You’ll want…
-

MEET THE PATIENTS WHERE THEY ARE: a new perspective on translational research in the field to accelerate precision oncology
Team members of the Judith Tam ALK Lung Cancer Research Initiative ventured out to Nashville on July 18th for the 2024 ALK Positive Summit, to embark on an unprecedented research blood collection which took place July 19th and 20th. This was the culmination of 5 months of intense visioning with ALK Positive, Inc and sculpting…
-

Discovering Insights Beyond Clinical Trials: Exploring ALK-Positive Lung Cancer Treatment
Clinical trials are the gold standard for evaluating new treatments in medicine. They offer a structured approach, where patient groups are carefully selected, treatments are administered, and results are meticulously followed over time. This controlled environment allows for a deep understanding of how treatments perform in specific patient populations, free from the confounding factors that…
-

Special series on “ALK-positive NSCLC” in the Translational Lung Cancer Research (TLCR) journal.
About two years ago (before Dr. Ken Culver was hired as ALK Positive Inc Director of Research and Clinical Affairs, and Colin Barton was still leading the ALK Positive Inc Medical Committee), Colin received an email from Dr. Justin Gainor and Dr. Jessica Lin from Massachusetts General Hospital, inviting ALK Positive Inc to contribute to…
-

Introducing ALK Positive Australia Inc. An interview with Deputy Chairperson, Graham Hall
Can you share with our readers the founding story of the ALK Positive Australia? What inspired the establishment of the organisation. I, like many others, including the other founders, felt at initial diagnosis that it was difficult to find local, relevant information about ALK+ Lung Cancer and I was dubious of heading to Facebook for…
-

Gilteritinib for the Treatment of ALK positive non-small cell lung cancer (NSCLC)
This trial is for patients with Stage 4 ALK positive NSCLC that have progressed on an earlier generation ALK TKI AND lorlatinib, and on any number of other standard-of-care or trial treatments. The trial drug is gilteritinib (aka Xospata), which was approved by the FDA in 2018 for a type of leukemia, but has been…
-

Vegan Tuscan Chickpeas A recipe by chef and fellow ALKie, Juli Posner
When we think of Superfoods, chickpeas are not necessarily what comes to mind, but chickpeas have many surprising health benefits. They contain important vitamins and minerals (B, B6, folate and vitamin E), they have protein, lots of fiber, and all that fiber may actually keep you feel fuller longer, keeping your weight in check.They are…
-

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
CAMBRIDGE, Mass., May 16, 2024 /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) to NVL-655 for the treatment of patients with locally advanced or…


